Sentences with phrase «cell immunotherapy trial»

«CD22 CAR T - cell immunotherapy trial open for children and young adults whose leukemia escapes CD19 CAR T - cell therapy.»

Not exact matches

Related Content Juno Halts Development of CAR T - Cell Cancer Immunotherapy Candidate JCAR015 Two More Deaths Reported in Juno Car - T Trial

Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

Priscilla N. Kelly Associate Editor Education: B.Sc., University of Western Australia; Ph.D., University of Melbourne Areas of responsibility: Preclinical development, translational medicine, cancer immunotherapy, drug discovery, clinical trials, gene and cell therapy E-Mail: [email protected]

Researchers are also working to develop a trial where they will reprogram CAR T cells to identify the CD19 and CD22 proteins simultaneously, enabling them to target the cancer cells from more than one angle with the initial round of T - cell immunotherapy.

Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.

The Johns Hopkins team tested ImmunoMap's ability to correlate immune responses on receptor sequencing data from T - cells in the tumors of 34 patients with cancer enrolled in a nationwide clinical trial of the immunotherapy drug nivolumab.

Wherry, together with his colleagues in the Parker Institute for Cancer Immunotherapy at Penn, are involved in multiple checkpoint - related trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.

A phase I clinical trial and a phase III clinical trial have been completed for a T - cell based immunotherapy and IL - 13 bacterial toxin fusion protein respectively, both with promising outcomes.

My interest and expertise in immunotherapy started in early 1990s with animal models of IL - 2 and IL - 15 cytokines and natural killer cell development, continued with high dose IL - 2 studies and subsequently Phase I - III trials with both CTLA - 4 and PD1 / PDL -1 checkpoint inhibitors.

Members of CRI's Cancer Immunotherapy Consortium (CIC) and the Immunoguiding Program (CIP) of the Germany - based Association for Cancer Immunotherapy (CIMT) announce the completion of the Minimal Information About T cell Assays (MIATA) Project to establish baseline requirements for reporting the results of T cell immune monitoring in clinical trials.

A collaborative group including the CRI Cancer Immunotherapy Consortium (CIC), the Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP), and scientists at Stanford University launch the Minimal Information About T cell Assays (MIATA) Project, the first systematic effort to establish a framework for reporting immune monitoring data from T cell assays used in clinical trials, with the goal of fostering reliability of data to facilitate meaningful interpretation, comparison, and meta - analysis across clinical trials.

The «TGF beta» clinical trial, named for one of the elements that distinguish this approach, is part of an emerging class of immunotherapies that employ adoptive cell transfer.

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.

There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.

This treatment represents a second generation approach to the same telomerase loaded, dendritic cell vaccination immunotherapy strategy that has been tested in two previous clinical trials of our AST - VAC1 product.

With the recent announcement that a first - line immunotherapy trial for non-small cell lung cancer (NSCLC) is positive for survival improvement, I can see the standard of care for lung cancer patients radically changing over the next few years.

Tags: aspirin, Bezos, bioengineering, Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cancers

Weinberg uses a similar «hitting the gas» approach to immunotherapy, targeting the T cell co-stimulator OX40 with a drug now in clinical trials.

Researchers are working to improve stem cell transplants so that they don't require immune - depleting chemotherapy beforehand, and clinical trials evaluating novel immunotherapy approaches, such as CAR T cells, that might be able to help young patients while sparing them the debilitating side effects.

The team will identify genetic and epigenetic features in CAR T cells and / or cancer cells that will help predict which patients will respond to the immunotherapy, with an eventual goal of initiating clinical trials that employ a combination of approaches to therapy.

A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.

He was given one more weapon to try before he was out of options: a clinical trial using CAR - T cell immunotherapy.

If clinical trials of anti-PD-1 continue to show promising results, cancer patients may soon have access to another powerful immunotherapy for the treatment of numerous cancers, including melanoma, non-small cell lung cancer, and other solid tumors.

The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes.